# Bacillus coagulans idrc019 Attenuates Irritable Bowel Syndrome by Revealing Multimodal Protective Mechanisms

## TL;DR

This study identifies a probiotic strain of Bacillus coagulans that helps treat irritable bowel syndrome by improving gut health through multiple mechanisms.

## Contribution

The study identifies a specific strain of Bacillus coagulans with proven efficacy and reveals its multimodal mechanisms in treating IBS.

## Key findings

- Bacillus coagulans idrc019 survives well in gut conditions and colonizes effectively.
- The strain alleviates IBS symptoms by reducing inflammation and hypersensitivity in an animal model.
- It improves gut health through immune, microbial, and metabolic regulation.

## Abstract

Bacillus coagulans has attracted widespread attention in the treatment of irritable bowel syndrome due to its multiple probiotic functions, yet its specific molecular mechanisms remain unclear, and the efficacy of probiotics exhibits significant strain specificity, posing a key bottleneck for practical application. To address this, this study obtained a bile salt-tolerant B. coaguans idrc019 through in vitro screening. This strain demonstrated strong survival and germination in simulated gut conditions, supporting effective intestinal colonization. Further evaluation in an IBS animal model revealed that idrc019 alleviated visceral hypersensitivity and colonic inflammation in a dose-dependent manner. Through enhanced intestinal barrier integrity, microbiota modulation (e.g., Actinobacteria restoration), and elevated metabolites (e.g., kynurenine), the strain exerted IBS-alleviating effects via synchronized immune, microbial, and metabolic regulation. Our findings offer a mechanistically grounded probiotic candidate, underscore functional screening as a critical strategy, and pave the way for clinical application.